Odonate Therapeutics, Inc.
ODTC · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $21 | $342 | $1,051 | $870 |
| Gross Profit | -$21 | -$342 | -$1,051 | -$870 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $36,483 | $117,041 |
| G&A Expenses | $0 | $0 | $0 | $10,392 |
| SG&A Expenses | $796 | $3,577 | $9,288 | $10,392 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$870 |
| Operating Expenses | $796 | $3,577 | $45,771 | $126,563 |
| Operating Income | -$817 | -$3,919 | -$46,822 | -$127,433 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $10,261 | $13,557 | -$21,493 | $1,083 |
| Pre-Tax Income | $9,444 | $9,638 | -$68,315 | -$126,350 |
| Tax Expense | $2,119 | -$33,302 | $0 | $0 |
| Net Income | $7,325 | $42,940 | -$68,315 | -$126,350 |
| % Margin | – | – | – | – |
| EPS | 6.818 | 39,375.729 | -48,889.111 | -102,517.747 |
| % Growth | -100% | 180.5% | 52.3% | – |
| EPS Diluted | 6.805 | 39,311.069 | -48,889.111 | -102,517.747 |
| Weighted Avg Shares Out | 1,074 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 1,076 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $21 | $342 | $1,051 | $870 |
| EBITDA | $9,465 | $9,980 | -$67,264 | -$125,480 |
| % Margin | – | – | – | – |